Press

Mindset Pharma Announces Further Preclinical Results for its 5-MeO-DMT-Inspired Drug Candidate.

Sep 20 • 2 min read

Quick Take: Mindset has announced that its preclinical trials for its DMT-inspired candidate MSP-4018 have shown strong preclinical efficacy and safety data. Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today…

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

Sep 20 • 7 min read

Quick Take: Delic has announced a merger with Arizona-based ketamine infusion clinic company KWC. KWC operates 10 clinics across multiple states, cementing Delic’s position as the largest ketamine health provider in the country. Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform today announced it has entered into a binding merger agreement…

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Sep 17 • 3 min read

Quick Take: MagicMed, a privately-held biotechnology company with a focus on DMT and psilocybin, has been acquired by Enviric Enveric Biosciences (NASDAQ: ENVB), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. (“MagicMed”), a privately-held biotechnology company focused on…

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Sep 16 • 3 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances. The IP was developed together with inventor Matthias Grill PhD, founder and CEO…

Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway

Sep 16 • 4 min read

Quick Take: Awakn will acquire a 100% interest in Axon, a ketamine-assisted psychotherapy clinic in Norway. Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435